Schrödinger closes latest financing, raising total of $110 million

New York-based Schrödinger yesterday announced that several new investors have joined its latest funding round, which was completed with a total raise of $110 million to support continued advancement of the company’s industry-leading computational platform and expansion of its therapeutic pipeline.

New investors include Invus, Pavilion Capital, Oculus co-founder Michael Antonov through his investment fund, Tubus Management, Laurion Capital Management, and others. Previous investors in the round included the Bill and Melinda Gates Foundation Trust, WuXi AppTec’s Corporate Venture Fund, Deerfield Management, Baron, Qiming Venture Partners, and GV (formerly Google Ventures).

“Our platform has been validated again and again across hundreds of targets in real-world drug discovery projects,” said Schrödinger chief executive Ramy Farid, adding:“We are committed to leveraging the platform to speed the discovery of new medicines, and we’re delighted to receive such broad support from investors to further our mission.”